New York State Common Retirement Fund Has $703,000 Position in Sarepta Therapeutics, Inc. $SRPT

New York State Common Retirement Fund lessened its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 71.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,471 shares of the biotechnology company’s stock after selling 93,091 shares during the quarter. New York State Common Retirement Fund’s holdings in Sarepta Therapeutics were worth $703,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in shares of Sarepta Therapeutics during the third quarter worth $185,000. Hussman Strategic Advisors Inc. raised its position in Sarepta Therapeutics by 33.3% during the 3rd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biotechnology company’s stock worth $1,619,000 after purchasing an additional 21,000 shares during the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new position in Sarepta Therapeutics during the 3rd quarter worth about $89,000. Mitsubishi UFJ Trust & Banking Corp bought a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at about $442,000. Finally, Covestor Ltd increased its stake in shares of Sarepta Therapeutics by 1,081.8% in the third quarter. Covestor Ltd now owns 2,789 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 2,553 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer owned 193,300 shares in the company, valued at approximately $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.60% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $18.33 on Wednesday. The firm has a market capitalization of $1.92 billion, a P/E ratio of -6.09, a P/E/G ratio of 0.46 and a beta of 0.39. The firm’s 50-day moving average price is $21.39 and its 200-day moving average price is $20.13. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $111.59.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SRPT. Piper Sandler lifted their price objective on Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, October 30th. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research report on Tuesday, January 27th. Wedbush lifted their target price on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. Finally, Barclays started coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price target on the stock. Nine investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $33.84.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.